Zinc-(II) 2,9,16,23-tetrakis (methoxy) phthalocyanine: potential photosensitizer for use in photodynamic therapy in vitro.
Photodynamic therapy (PDT) is an innovative treatment for several types of malignant and non-malignant disease. In the present study, ZnPcOCH(3) was investigated on a human larynx-carcinoma cell line (Hep-2) for its use in PDT. This drug exhibited favourable properties as a photosensitizer in vitro because ZnPcOCH(3) is able to penetrate efficiently in the cytoplasm of cultured cancer cells and is partially localized in lysosomes. The results show that ZnPcOCH(3)-PDT-induced apoptosis by caspase dependent pathway. The new compound shows a good photosensitizing efficiency in vitro on Hep-2 cells, encouraging further in vivo studies.
Yslas
Edith I
EI
Departamento de Biología Molecular, Universidad Nacional de Río Cuarto, Agencia Postal Nro 3, X580BYA Río Cuarto, Argentina.
Durantini
Edgardo N
EN
Rivarola
Viviana A
VA
D053148:Caspase 3 / Q000378:metabolism; D020169:Caspases / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000187:drug effects / Q000648:ultrastructure; D053938:DNA Fragmentation / Q000187:drug effects; D006801:Humans; D020287:In Situ Nick-End Labeling; D008247:Lysosomes / Q000187:drug effects / Q000648:ultrastructure; D008928:Mitochondria / Q000187:drug effects / Q000648:ultrastructure; D009942:Organometallic Compounds / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology*
D009942:Organometallic Compounds; D017319:Photosensitizing Agents; C521683:zinc-(II) 2,9,16,23-tetrakis (methoxy) phthalocyanine; D053148:Caspase 3; D020169:Caspases